CTLA4 and neoplasm: Tumor mutational burden and a T-cell-inflamed gene expression profiles were independently predictive of response to the PD-1 antibody pembrolizumab [126]; high concentrations of the CCR5 ligand’s CCL3 and MIP-1-β, seen in pretreatment tumor specimens, were associated with worse patient overall survival after anti-CTLA-4 and carboplatin and paclitaxel treatment was given for melanoma [126].